Overview

Study of CT071 Injection in RRMM or PPCL

Status:
Not yet recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Phase:

Early Phase 1

Details

Lead Sponsor:

Shanghai Changzheng Hospital

Collaborator:

CARsgen Therapeutics Co., Ltd.